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Cell birth and cell death are tightly regulated in time and space, both during the 
development of an organism and at maturity. With the exception of the passive dying of 
cells in necrosis, cell death is ‘programmed’, serving a variety of processes like the 
sculpturing of the embryo, the maintenance of tissue homeostasis, the termination of 
immune responses, and the restriction of infections. Programmed cell death is often 
equated with apoptosis [1]. Many diseases, including cancer, autoimmunity and 
degenerative disorders, could be caused by disturbed regulation of apoptosis [2]. The 
morphological changes that can be seen in apoptotic cells are cell shrinkage, loss of contact 
with neighboring cells, chromatin condensation, blebbing of the plasma membrane, and 
fragmentation into compact membrane-enclosed structures called apoptotic bodies [3, 4]. 
The apoptotic bodies are engulfed by macrophages and thus are removed from the tissue 
without causing an inflammatory response. In contrast, necrosis is characterized by rapid 
swelling of cells that have been exposed to stresses such as chemical or mechanical injury, 
or environmental changes that lead to irreversible damage. Eventually, these cells burst and 
spill their contents into the extracellular space causing a strong inflammatory response in 
the surrounding tissue [5].  
Apoptosis is an intriguing process, involving many different factors. There are four 
major functional groups of molecules involved in triggering and affecting the apoptotic 
process. These are members of the tumor necrosis factor receptor (TNF-R) family, the 
cysteine-dependent aspartate-specific proteases (caspases), the adaptor proteins that control 
the activation of initiator caspases, and members of the B-cell lymphoma 2 (Bcl-2) family 
of proteins [6]. The apoptosis signaling pathways can be divided in the extrinsic and 
intrinsic pathways. The extrinsic pathway is receptor-mediated, whereas the intrinsic 
pathway is mitochondria-mediated. Both pathways converge on a common machinery of 
cell destruction that is activated by the caspase family (Fig. 1) [6, 7].  
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Figure 1. Schematic representation of some major apoptotic signaling pathways. Apoptosis can be 
induced in response to various signals from inside and outside of the cell, e.g. by ligation of death receptors 
or by cellular stress triggered by oncogenes, irradiation, or drugs. Signals emanating from death receptors 
activate the death inducing signaling complex (DISC) which mediates activation of the initiator caspase-8. 
Caspase-8 activates the caspase cascade which eventually leads to apoptosis. Mitochondrial apoptotic 
signaling includes the release of cytochrome c from the mitochondrial intermembrane space to the cytosol 
where it contributes to the formation of the apoptosome, a complex of cytochrome c and the adaptor protein 
Apaf-1 which forms in the presence of dATP. The apoptosome activates caspase-9 which then activates the 
caspase cascade which leads to the characteristic morphological and biochemical features of apoptosis. 
Figure from Gewies 2003 [1]. 
 
A group of proteins important for initiating the apoptotic process are members of the 
TNF-R family including TNFR-1, Fas/CD95, and TRAIL receptors. Depending on the cell 
type and type of signal, these receptors can trigger proliferation, survival, differentiation, 
or cell death [8]. These receptors are activated by a group of structurally related ligands 
that belong to the TNF-ligand family; upon binding the receptor-ligand complexes 
oligomerize and recruit intracellular adaptor proteins. The members of the TNF-R family 
are characterized by having a death domain (DD) in their intracellular region by which 
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they bind adaptor proteins such as FADD and TRADD [9]. Interactions between DDs in 
members of the TNF-R family and that of the adaptor proteins is required for the efficient 
recruitment of the caspases and allows caspase aggregation and activation. Caspase 
recruitment and aggregation are themselves mediated by death effector domains (DED) or 
by caspase recruitment domains (CARD) [10]. 
The caspase family includes proteins that are the central initiators and executors of 
apoptosis and at least 14 members have been identified in mammals [6, 11]. Caspases are 
synthesized as inactive zymogens, called procaspases, which carry a prodomain at their N-
terminus followed by a large and a small subunit that are sometimes separated by a linker 
peptide. Upon maturation, the procaspases are proteolytically processed resulting in a 
small and a large subunit. A heterotetramer consisting of two small and two large subunits 
then forms an active caspase. The apoptotic caspases can be divided into a group of 
initiator caspases including procaspases-2, -8, -9, and -10, and into a group of effector 
caspases including procaspases-3, -6, and -7 [12]. Recruitment and activation of the 
initiator caspases is achieved by binding to adaptor proteins, in contrast to the effector 
caspases that are unable to interact with the adaptor proteins and that are instead activated 
by upstream active caspases [6].  
A final group of important proteins that control apoptosis is the Bcl-2 family. Members 
of this family are divided into two groups, a prosurvival group including Bcl-2, Bcl-xL, 
A1, and Mcl-1, and a proapoptotic group including Bax, Bak, Bid, Bad, Bim, Bik, Bmf, 
HRK, Puma, and Noxa [2, 13]. There is no agreement on how the Bcl-2 family controls 
apoptosis. There are two proposed models: one proposing that Bcl-2 members directly 
control caspase activation, whereas the other claiming that they mainly act by guarding 
mitochondrial integrity [2]. The first model speculates that Bcl-2 might control the 
activation of several initiator caspases that act upstream or independently of the 
mitochondria. These caspases, in turn, process proteins that activate Bax and Bak that 
produce damage to organelles resulting in amplification of the proteolytic cascade. The 
second model claims that in a viable cell, the proapoptotic Bcl-2 family members such as 
Bax and Bak are antagonized by antiapoptotic members such as Bcl-2. In response to an 
apoptotic stimulus, proapoptotic members are activated by transcriptional up-regulation 
(Bax, Noxa), subcellular relocalization (Bim, Bmf), dephosphorylation (Bad), or 
proteolysis (Bid). Activated proapoptotic members then inactivate antiapoptotic members 
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and subsequently Bax and Bak insert into the mitochondrial membrane where they 
contribute to the release of cytochrome c [2, 14, 15]. Cytochrome c release is specific for 
mitochondrial apoptotic signaling as will be described in the next section. 
As mentioned above, the apoptotic signaling pathways are divided into extrinsic and 
intrinsic pathways. The extrinsic pathway involves the TNF receptor family which upon 
activation recruits adaptor proteins such as FADD or TRADD through their DDs. The 
adaptor proteins recruit procaspase-8 through the DEDs or CARDs and together, the 
receptors, the adaptor proteins and the procaspases form a death inducing signaling 
complex (DISC). The local concentration of several procaspase-8 molecules leads to their 
autocatalytic activation and release of active caspase-8. Active caspase-8 then processes 
downstream effector caspases which subsequently cleave specific substrates resulting in 
cell death (Fig. 1) [1, 6].  
The second pathway that leads to apoptosis is the intrinsic pathway. This pathway is 
activated in response to cell death signals originating from inside the cell and is mediated 
by mitochondria that release cytochrome c from the intermembrane space. Apoptotic 
signaling from inside the cell can be initiated by anticancer drugs, DNA damaging agents, 
kinase inhibitors, hypoxia, growth factor withdrawal, and UV and ionizing radiation [16]. 
In the cytosol cytochrome c and the adaptor protein Apaf-1 form a so-called apoptosome in 
the presence of  dATP [17]. The apoptosome activates caspase-9 which in turn activates 
the caspase cascade by activating caspase-3 (Fig. 1) [18]. The resulting activation of the 
caspase cascade can be inhibited by inhibitors of apoptosis proteins (IAPs) which can be 
up-regulated in response to survival signals [19, 20]. Crosstalk between the extrinsic and 
intrinsic pathway is mediated by Bid, a proapoptotic Bcl-2 family member. Caspase-8 
mediated cleavage of Bid increases its activity and results in translocation to the 
mitochondria where it acts in concert with Bax and Bak to induce cytochrome c release, 
thereby activating the intrinsic pathway [19]. 
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Apoptosis and cancer 
For developing a tumor, tumor cells have to avoid apoptosis that is induced not only by 
unregulated oncogene expression, but also by limited supplies of growth factors, oxygen, 
or nutrients [21]. For tumors to become invasive and metastatic the cancer cells must, 
besides avoiding apoptosis, also generate their own growth signals, become insensitive to 
anti-growth signals, be able to replicate in a limitless manner and be able to induce and 
sustain angiogenesis [22]. Several genes that code for proteins involved in the regulation of 
apoptosis have been shown to be mutated or to exhibit altered expression in tumor cells. 
The tumor suppressor gene p53 is the most commonly mutated gene in human cancers. p53 
is involved in regulation of gene transcription, DNA synthesis, DNA repair, senescence, 
apoptosis, and is a key regulator of the cell cycle, controlling the transition from the G1 
phase to the S phase [23, 24]. Under conditions conducive to DNA damage, p53 can either 
induce apoptosis or arrest the cell cycle for DNA repair. Mutated p53 has a prolonged half-
life, leading to accumulation of the abnormal protein not able to induce apoptosis [25]. 
Also important is Bcl-2 which often is over-expressed in cancer cells. Increased expression 
of this antiapoptotic protein is associated with decreased susceptibility of many tumor cells 
to undergo apoptosis in response to anticancer treatments [6]. Thus the down-regulation of 
apoptosis seems to be important for malignant transformation.  
The prostate 
The prostate is a gland of the male reproductive system and produces some of the fluid 
for the semen and may facilitate sperm motility [26]. Normally the prostate is quite small, 
nearly the same size of a chestnut. It is located in front of the rectum, just below the 
bladder and wraps around the urethra. The prostate is made up of at least three distinct cell 
types including secretory epithelial cells, basal cells and neuroendocrine cells that can be 
distinguished by their morphological characteristics, functional significance, and relevance 
for carcinogenesis. The epithelial cells are androgen-dependent for growth and secrete 
PSA. The basal cell layer is not dependent on androgens and is believed to contain stem 
cells. A stroma that includes fibroblasts, smooth muscle, nerves and lymphatic cells 
surrounds the gland [26].  
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Prostate cancer  
Prostate cancer is the sixth most common cancer in the world and the third leading 
cause of death in men [27]. It has become a major public health problem, being prevalent 
in Scandinavian countries and with the highest incidence and mortality rates in African-
Americans. In contrast, prostate cancer is relatively uncommon in Asian populations [28]. 
In the United States the age-adjusted incidence rate is 173.8 cases per 100,000 men from 
1998 to 2002. The age-adjusted death rate in this time period was 30.3 per 100,000 men 
[29]. Norway has an incidence rate of prostate cancer with 77 cases per 100,000 men in 
average from 1997 to 2002. This is in contrast to 24.7 cases per 100,000 men in the time 
period 1953 to 1957 [30]. The increase that is observed in prostate cancer incidence might 
be due to early detection methods including increased screening of prostate-specific 
antigen (PSA) levels rather than true differences in underlying risk [31]. 
Epidemiologic studies have provided a great amount of information regarding risk of 
prostate cancer. Risk factors can be classified as endogenous or exogenous although some 
factors belong to both groups. Endogenous risk factors include family history, hormones, 
race, aging, and oxidative stress [31]. Results from multiple studies provide evidence for 
aggregation of prostate cancer in families. Segregation analyses support the existence of 
high-risk alleles for prostate cancer and twin studies have estimated that a substantial 
fraction of more than 40% of the disease has a genetic component [28]. Abundant 
biological data suggest the importance of androgens in the growth and maintenance of the 
prostate and the fact that prostate cancer regresses after androgen ablation or anti-androgen 
therapy makes androgens an important risk factor for prostate cancer [32]. Differences in 
prostate cancer risk by race may reflect differences in diet, differences in the detection of 
the disease and genetic differences. As previously pointed out, incidence rates are highest 
among African-American men [31]. In addition, the frequency of prostate cancer increases 
dramatically with age, almost 90% of the cases arise after 60 years of age [30].  
The exogenous risk factors for prostate cancer include diet, environmental agents, and 
industrial and occupational exposures [27, 31]. Dietary influences such as red meat, high 
fat (elevated risk), and antioxidants (lowered risk) have been implicated with prostate 
cancer incidence and mortality, as has the lack of fruits and vegetables in one’s diet [28, 
33]. Environmental agents and industrial and occupational exposures are especially 
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exemplified by one class of environmental agents, endocrine disrupting chemicals (EDCs). 
These chemicals can be defined as agents that positively or negatively alter hormone 
activity and ultimately lead to effects on reproduction, development, and carcinogenesis, 
particularly of the reproductive organs [31]. In fact, the risk of prostate cancer among 
Asians increases when they immigrate from Asia to North America, implicating the 
environment and lifestyle-related factors in causing prostate cancer as pointed out above 
[34]. 
Most prostate tumors are adenocarcinomas, sharing numerous common features with 
other prevalent epithelial cancers, such as breast and colon cancer [35]. At some point 
during the disease, androgen-dependent epithelial prostate cells progress to an androgen-
independent state in which the cells become more prone to metastasise and more resistant 
to apoptosis. The molecular events involved in the transformation of the normal prostate to 
a hormone insensitive cancer is a process that is poorly understood, despite the recognition 
of various events during prostate cancer tumorigenesis such as the deregulation of 
receptors, oncogenes, and tumor-suppressor genes [27]. By the time of prostate cancer 
diagnosis, prostate cells may have undergone somatic mutations, gene amplifications, gene 
deletions, chromosomal rearrangements, and changes in DNA methylation pattern [33]. 
Losses of genetic material are much more common than gains or amplifications, indicating 
that tumor-suppressor genes, which are believed to harbour the frequently deleted regions, 
probably play an important role in the tumorigenesis of the prostate [36]. Somatic targets 
of genomic damage include homeodomain-containing transcription factor 3.1 (NKX3.1), a 
candidate ‘gatekeeper’ gene [37, 38], phosphatase and tensin homolog deleted on 
chromosome ten (PTEN), a tumor-suppressor gene [39, 40], and the androgen receptor 
(AR) [33, 41-43]. Many of the chromosomal losses can be detected already in the early 
stages of prostate cancer, whereas gains and amplifications are mostly seen in hormone-
refractory tumors [36].  
Prostate development and normal prostate function require androgens, testosterone and 
5α-dihydrotestosterone (DHT), which through binding to AR induce its transcriptional 
activity [44]. The AR belongs to the steroid receptor subfamily which is part of the nuclear 
receptor superfamily that is believed to be derived from a common ancestor [45]. Like 
other members of this family it is characterized by an N-terminal domain for 
transcriptional regulation, a centrally located DNA-binding domain (DBD), and a ligand-
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binding domain at the C-terminal end (LBD) [44]. The AR gene is located on the X-
chromosome and therefore is single-copy in males, which allows for the phenotypic 
manifestation of mutations [44]. The effect of androgen on cell death occurs predominantly 
by interference with caspase activation and the inhibition of caspase cleavage in both the 
extrinsic and intrinsic cell death pathways [35, 46]. In the prostate, androgenic action is 
determined not only by androgen concentration but also by several other factors, such as 
the levels of the androgen receptor and its coactivators, the presence of growth factors, and 
perhaps factors yet to be identified [32].  
Since the prostate is dependent on androgens for its growth and maintenance, one of the 
most common treatments for advanced prostate cancer is androgen-ablation therapy, 
involving the removal of androgens and estrogens by chemotherapeutic agents or 
castration, which effectively results in tumor regression caused by massive apoptosis of 
androgen-dependent cancer cells. Unfortunately, some prostate cancer cells are androgen-
independent, survive in an androgen deprived environment and so the prostate cancer 
relapses into a highly aggressive and metastatic state that is androgen independent [36, 47]. 
Defining the signaling pathways that are induced by the androgen receptor is very 
important since there is evidence that in advanced androgen-independent prostate cancer 
the androgen receptor signaling pathways may be functioning and may have a role in the 
progression of the disease [48]. Tumors that have become androgen-independent show an 
increase in androgen-dependent genes such as PSA and kallikrein-2 [48]. Furthermore, 
over-expression and somatic mutations of the AR gene often appear in androgen-
independent cancer [44, 49, 50]. These mutations can lead to increased sensitivity of the 
receptor to low levels of circulating androgens and increases the receptors ability to 
recognize a broadened spectrum of ligands as potent agonists of AR action [41, 43]. In 
addition, the presence of AR gene amplification in androgen-independent prostate cancer 
may reflect an adaptation of the cancer cells to the low levels of circulating androgens [42].  
Hormonally regulated cell death and cell proliferation are balanced to maintain the 
normal size of the prostate and it has been shown that 85% of the cells in the rat prostate 
disappear within two weeks after castration due to increased levels of apoptosis [51]. In 
contrast, prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer, and 
early invasive carcinomas are characterized by a seven- to ten-fold increase in the 
proliferation rate, whereas advanced and metastatic prostate cancers also display an 
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approximately 60% decrease in apoptosis [35]. Decreased apoptosis in prostate cancer cells 
is characterized by apoptosis suppressing genes that code for proteins such as IAPs and 
Bcl-2 [52]. IAP family proteins represent critical regulators of apoptosis that serve as 
inhibitors of the caspase family. Alteration in the expression of several IAP family proteins 
occur commonly and often simultaneously in prostate cancers and is suggested to occur 
early in the pathogenesis of this disease [53]. Antiapoptotic Bcl-2 has been found to be 
expressed in clinical samples of androgen-dependent and –independent prostate tumors. 
Over-expression of Bcl-2 prevents cells from initiating the process of apoptosis in response 
to a number of different stimuli and the expression of this protein has been associated with 
androgen-independent progression, treatment resistance, and is commonly associated with 
a poor prognosis in prostate cancer [47, 54].  
To date no curative treatment is found for androgen-independent prostate cancer. In 
fact, many of the antiproliferative chemotherapeutic agents only lead to cancer cell death if 
the cells are proliferating. Cancer cells that are not proliferating at the time of treatment 
will not be affected. It is known that more than 90% of prostatic cancer cells in an 
individual patient are not proliferating and thus are resistant to normal cytotoxic therapy 
[20, 47]. Much work is done to improve the therapeutic arsenal in treatment of advanced 
prostate carcinoma and hopefully this will help to improve the duration and quality of life 
of prostate cancer patients.  
Mitogen-activated protein kinases (MAPKs) 
Nearly every cellular process is regulated at least to some degree by protein 
phosphorylation. In particular, signal transduction pathways employ protein 
phosphorylation and dephosphorylation as a mechanism to transmit information to 
different cellular compartments to elicit distinct physiological responses. Target proteins 
are phosphorylated at specific sites by protein kinases and dephosphorylated at the same 
sites by protein phosphatases. One of the best-studied groups of protein kinases is that of 
the mitogen-activated protein kinases (MAPKs). MAPKs are important mediators of signal 
transduction and play a key role in the regulation of many cellular processes [55, 56]. The 
MAPKs are serine/threonine kinases that are phosphorylated and activated on a Thr-X-Tyr 
motif by diverse stimuli such as cytokines, growth factors, and environmental stress. The 
MAPK cascades are composed of three protein kinases acting in series. A MAPK is 
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activated by a MAPK kinase (MAPKK) which in turn is activated by a MAPKK kinase 
(MAPKKK). In order to increase the variation of possible responses to various types of 
stimuli, a diverse range of MAPKKKs activate a smaller amount of MAPKKs which then 
in turn activate a few MAPKs. In addition, some MAPKKKs and MAPKKs are not 
specific for a particular substrate, contributing to a complex web of crosstalk reactions 
between the cascades of kinases [57]. 
The three major and best studied MAPK pathways result in the activation of 
extracellular signal regulated kinases (ERKs), c-Jun N-terminal kinases/stress-activated 
protein kinases (JNKs/SAPKs), and p38 MAPKs (Fig. 2). These MAPKs are expressed in 
a wide variety of tissues and the cellular response of these pathways depends on the nature 
of the stimulus and the duration of each kind of signal [55]. The ERK pathway is mainly 
involved in growth, differentiation, and development while JNK and p38 MAPK pathways 
are involved mainly in inflammation, apoptosis, growth, and differentiation [57].  
Since there is a staggering number of MAPK substrates and diverse biological 
processes that they regulate, it raises the question of how MAPK substrate specificity is 
determined and regulated. In addition to dephosphorylation by MAPK phosphatases, as 
will be discussed later, there are mainly two mechanisms involved, the docking interaction 
and the scaffolding. MAPKs utilize the common docking (CD) domain for interactions 
with MAPKKs, substrates, and phosphatases and another site, the glutamate-aspartate (ED) 
site, could determine the docking specificity towards the substrates [58]. In addition, 
MAPK interacting proteins have a so-called D domain and removal of this domain was 
shown to prevent recognition of the cognate MAPK [58]. The other mechanism involves 
scaffolding proteins that interact with several components of the MAPK cascades to tether 
both enzymes and substrates specifically to achieve accurate signal transduction. They do 
not contain any intrinsic enzymatic activity but possess a structure that enables them to 
recruit different factors of a specific pathway simultaneously [59]. Several scaffold 
proteins such as KSR and MP-1 are known to function as ERK scaffolds whereas for 
example the JNK-interacting protein (JIP) family includes members that are scaffolds for 




The ERK (p44 ERK1/p42 ERK2) pathway is an evolutionary conserved pathway that is 
involved in the control of many fundamental cellular processes that include cell 
proliferation, survival, differentiation, apoptosis, motility, and metabolism [55, 61]. ERK1 
and ERK2 are activated by the dual specificity MAPK kinases MEK1 and MEK2, which 
are activated by Ras GTPases and Raf. Following activation, ERKs translocate to the 
nucleus and phosphorylate a variety of substrates such as the transcription factors c-Myc, 
Elk-1, and Ets-1 (Fig. 2) [57]. The ERK pathway is known to control growth and survival 
of a broad spectrum of human tumors. In fact, many tumors have activating mutations in 
Ras GTPases and Raf that result in activation of the ERK signaling cascade [62]. 
 
 
Figure 2. A simplified scheme of the MAPK signaling cascades. Three major groups of MAP kinases, 
ERK, JNK, and p38 MAPK are activated by various extracellular stimuli, leading to phosphorylation and 
activation of different transcription factors. Figure from Viktorsson et al 2005 [6].  
 
p38 MAPK 
Another MAPK is p38 MAPK of which four isoforms (α, β, γ, and δ) have been 
identified. p38 MAPK signaling pathways are activated in response to extracellular stimuli 
such as UV light, heat, osmotic shock, inflammatory cytokines, and growth factors and the 
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cellular responses depend on cell type as well as the stimulus [63]. Activation of p38 
MAPK through either stress or cell surface receptors involves members of the Rho family 
of small GTPases, which can phosphorylate and activate the MAPKKKs MLKs, TAK1, 
and ASK1 [63]. These in turn activate MKK3 and MKK6 which directly activate p38 
MAPK. The p38 MAPKs control the function of kinases, phosphatases, or transcription 
factors such as ATF-2, MEF2, and Elk-1 (Fig. 2) [57].  
JNK 
The final major MAPK pathway results in the activation of JNK that has been 
implicated in apoptosis, oncogenic transformation, inflammation, development, and 
differentiation, as mentioned above [55]. In mammals, there are three JNK genes, JNK1, 
JNK2, and JNK3, each located on a different chromosome [64]. The JNK1 and JNK2 
genes are expressed ubiquitously, in contrast, the JNK3 gene has a more limited pattern of 
expression and is largely restricted to brain, heart, and testis. The three genes are 
alternatively spliced to create ten isoforms (Fig. 3) [65-67]. Similar to p38 MAPK, JNKs 
are activated by the Rho family of small GTPases, including Rho, Rac, and Cdc42. These 
proteins in turn activate MAPKKKs such as MEKK1-4 which then activate MKK4 or 7 
that are immediate upstream MAPKK of JNK. MKK4 and 7 are also activated by ASK-1, 
TAK-1 and MLKs (Fig. 2) [6, 67].  
As the name suggests, the JNKs have been characterized by their ability to associate 
with and phosphorylate regulatory sites in the N-terminus of the transcription factor c-Jun 
[68]. Phosphorylated c-Jun forms homodimers or heterodimers with active c-Fos, forming 
a so-called activator protein-1 (AP-1) that has the ability to recognize specific DNA 
sequences known as TPA-responsive elements (TRE), which are found in the regulatory 
regions of a variety of genes, including cell-cycle related and AP-1 genes themselves [69, 
70]. AP-1 activity can be regulated by dimer composition, transcription, post-translational 
modification, and interactions with other proteins [71-74]. In addition to c-Jun, JNK can 
also activate additional transcription factors such as ATF-2, Elk-1, and p53 (Fig. 2) [57, 
67, 75, 76]. Furthermore, JNK phosphorylates proteins that are not transcription factors 




Figure 3. Structural features of the JNK proteins. JNK protein kinases comprise 11 protein kinase 
subdomains (indicated as I-XI). The protein activation loop is located between domains VII and VIII and 
contain the threonine (T) and tyrosine (Y) residues that are phosphorylated for kinase activation. JNK1, 
JNK2, and JNK3 (in orange, light and dark blue, respectively) produce ten different isoforms by alternative 
splicing. The differences are indicated by the shaded regions. Two key alternative splicing sites are shown. 
The first between subdomain IX and X which results in altered substrate specificity, the second at the C-
terminus which results in a difference in length. Reproduced with permission from Nature Reviews Drug 
Discovery Manning et al 2003  Macmillan Magazines Ltd [66]. 
 
Studies on the roles of JNK1, JNK2, and JNK3 showed that mice with compound 
mutations in JNK1 plus JNK3 or JNK2 plus JNK3 are viable [79]. In contrast, compound 
mutations of the ubiquitously expressed JNK1 and JNK2 genes causes early embryonic 
death associated with decreased apoptosis in the hindbrain and increased apoptosis in the 
forebrain [79-81]. In addition, embryonic murine fibroblasts, disrupted for JNK1 and 
JNK2, were shown to be protected against UV-induced apoptosis [82]. Involvement of 
JNK3 in the death process was supported through studies with JNK3-/- mice that 
manifested severe defects in the apoptotic response in the hippocampus [83]. To 
summarize, gene disruption studies have demonstrated a role for JNK in the different 
cellular processes mentioned before. 
It has been proposed that JNK activation triggers apoptosis in response to many types of 
stress, including UV and γ-irradiation, osmotic stress, toxins, heat shock, anti-cancer drugs, 
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inflammatory cytokines, and several other stimuli [57, 66]. Induction of apoptosis might be 
due to transcription-dependent signaling (leading to secretion of death-ligands) or by 
transcription-independent signaling (leading to cytochrome c release from mitochondria) 
[69]. A strong activator of JNK is UV irradiation [19]. UV-induced JNK activation leads to 
increased transcription of c-Jun and c-Fos mediated through phosphorylation of 
transcription factors c-Jun, ATF-2 and Elk-1 and results in a large increase in activator 
protein-1 (AP-1) activity [84]. The activation of JNK was shown to be independent of 
damage to nuclear DNA, instead it was dependent on activation of various cell surface 
receptors, possibly through damage to cell membranes [84].  
Regarding prostate cancer, JNK is strongly activated and linked to cell death under 
stressful stimuli including cytotoxic drugs [85, 86]. Two inducers of JNK in the androgen-
responsive prostate cancer cell line LNCaP are 12-O-tetradecanoyl-13-phorbol-acetate 
(TPA) and thapsigargin (TG). TPA has been shown to induce apoptosis through up-
regulation of protein kinase C (PKC)-δ or -α  and activation of JNK [87]. The downstream 
signals of PKC that mediate TPA-induced apoptosis in LNCaP cells are currently unclear. 
TG is a potent inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase pump 
which results in a rapid increase in intracellular calcium ion [88]. Both TPA and TG have 
been reported to induce apoptosis in LNCaP cells whereas TPA does not induce apoptosis 
in the androgen-independent prostate cancer cell lines PC3 and DU145. In LNCaP cells 
apoptosis induced by these two agents was correlated with activation of JNK and specific 
inhibition of JNK reduced both TPA- and TG-induced apoptosis [89, 90]. Recently it was 
shown that androgens decrease TPA- and TG-induced cell death of prostate cancer cells 
and this is mediated through the down-regulation of JNK activation [91]. JNK and the 
other MAPKs can be inactivated by mitogen-activated protein kinase phosphatases 
(MKPs) that specifically dephosphorylate active MAPKs at phosphorylated tyrosine and 




MAPK phosphatases (MKPs) 
Dephosphorylation of the MAPKs is vital for their control and is achieved by removal 
of phosphate groups from either the threonine residue or the tyrosine residue, or both. 
Phosphatases that are required for inactivation of the MAPK pathways are the 
serine/threonine phosphatases, the tyrosine phosphatases, and the dual specificity 
phosphatases (DUSPs) that dephosphorylate both serine/threonine and tyrosine. The 
various phosphatases are able to dephosphorylate components of the MAPK pathways at 
different stages of the pathways [92, 93]. The DUSPs have been recognized as key players 
for inactivating MAPKs and have been designated mitogen-activated protein kinase 
phosphatases (MKPs) [94]. MKP-1 was the first MAPK phosphatase discovered in 1991 
[95]. To date there are fourteen known dual specificity phosphatases acting directly on the 
MAPKs (Table 1). As shown in Table 1, the MKPs have multiple names which make it 
difficult to distinguish them from each other. They are characterized by different 
subcellular localization (nuclear, cytosolic, or both), MAPK affinity, and structure and can 
be divided in groups according to these features. Furthermore, the great diversity among 
the MKPs and their MAPK affinity indicate an unexpected complexity for the negative 
regulation of MAPK signaling [96].  
Two domains, a catalytic and a non-catalytic domain, are specific for the MKPs. The 
carboxyl terminal of each phosphatase contains a catalytic domain. This domain consists of 
a highly conserved signature motif -HCXXXXXR- that has significant sequence homology 
to the VH-1 gene, coding for a phosphatase in vaccinia virus that was discovered in 1991 
[94]. The cysteine and arginine residues within this signature motif located in the active 
site loop and an additional highly conserved aspartate residue are essential for the 
dephosphorylation process [97]. The second domain is non-catalytic and is found in the 
amino-terminal. This domain contains two short regions of sequence homology with the 
catalytic domain of the cdc25 phosphatase which plays an important role in cell cycle 
regulation by removing inhibitory phosphates from tyrosine and threonine residues of 




Table 1. Overview over the different MKPs/DUSPs. This table summarizes the different features of the 
MKPs/DUSPs grouped by means of their structure. The human names, the mouse orthologue names, 
subcellular localization, MAPK affinity, and accession number are shown. The newly discovered 
phosphatase MKP-8 is not included in this Table [99]. The Table is modified from Farooq et al [94]. 









 Nuclear ERK » JNK ~ p38 NM_004090 
DUSP-
22/DSP2 
  P38 ~ JNK » ERK NM_020185 
Type I 
DUSP-14 MKP-6  ERK ~ JNK » p38 NM_007026 
DUSP-
1/hVH1 
MKP-1 Nuclear P38 ~ JNK » ERK NM_004417 
DUSP-
4/hVH2 




 Nuclear - NM_004419 
DUSP-
6/PYST1 




MKP-X Cytosolic - NM_001947 
DUSP-9 MKP-4 Nuclear/ 
cytosolic 




 Nuclear ERK » p38 ~ JNK NM_004418 
Type 
III 
DUSP-10 MKP-5 Nuclear/ 
cytosolic 
P38 ~ JNK > ERK NM_007207 
NM_144728 










Farooq et al group the MKPs by means of their structure and this divides them into four 
different groups (Fig. 4 and Table 1) [94].  
 Type I phosphatases are approximately 200 amino acid residues in length and 
contain only a catalytic domain characterized by the phosphatase signature 
sequence –HCXXXXXR-. Members of this group are VHR [100-104], DUSP22 
[105], and MKP-6 [106].   
 Type II phosphatases are 300-400 amino acid residues in length and contain a 
catalytic and a MAPK binding domain. Members of this group are MKP-1 [107-
110], DUSP2 [110, 111], MKP-2 [110], VH3 [112], MKP-3 [113-115], MKP-X 
[116], and MKP-4 [117].  
 Type III phosphatases have the catalytic domain, the MAPK binding domain, 
and in addition an N-terminal domain of unknown function. The only known 
member of this group is MKP-5 [118, 119].  
 Type IV phosphatases are 600-700 amino acids residues in length, contain the 
catalytic and MAPK binding domain and also a proline (P)-glutamate (E)-serine 
(S)-threonine (T) rich C-terminal. The function of the latter region, also called 
PEST,  remains to be elucidated although, in analogy with other PEST-like 
sequence containing proteins, it has been suggested that it may be involved in 
rapid degradation of the type IV MKPs through ubiquitin-mediated proteolysis 
[120]. This may provide an important regulatory mechanism for phosphatases in 
this group. Members of this group are MKP-7 [121] and DUSP8 [122]. 
Despite the knowledge about the domains of MKP family members, little is known 
about their atomic structure. To date, the atomic structures of the catalytic domain of VHR 
[123], MKP-3 [114], and DUSP-2 [111] have been determined. The conformation and 
positioning of key residues in both the catalytic domain and the so-called general acid loop 
are essential for their enzymatic activity [94]. Crystal structure studies also demonstrate 
that the dynamic interaction between the MAPK binding domain (MKB) and the catalytic 
domain is directly coupled to a MAPK-induced conformational change of the phosphatase 
catalytic site, which is required for optimal enzymatic activity [111]. Many of the MKPs 
exhibit catalytic activity only on binding to their substrates which then induces the 
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conformational change. This holds for MKP-1, MKP-2, MKP-3, MKP-X, and MKP-4, but 
is not the case for VHR [94] and VH3  which already are in an optimal conformation for 
catalysis [112]. 
 
Figure 4. Subgrouping of the MKP-family according to their structure. Members and description of 
the groups are pointed out in the text. DSP: catalytic domain, MKB: MAPK binding domain, NT: N-terminal 
domain, and PEST: proline (P)-glutamate (E)-serine (S)-threonine (T) rich C-terminal. Figure from Farooq 
et al 2004. 
Aim of the present study 
Previously it was shown that both TPA and TG induce apoptosis in androgen-
responsive LNCaP cells. In contrast, TPA did not induce apoptosis in the androgen-
independent prostate cancer cell lines PC3 and DU145. Apoptosis was correlated with 
activation of JNK and specific inhibition of JNK reduced both TPA- and TG-induced 
apoptosis [89]. Further research showed that androgens decrease TPA-and TG-induced cell 
death of prostate cancer cells and that this correlates with the down-regulation of JNK 
activation [91]. In addition, UV-induced JNK activation was also reduced in androgen 
treated LNCaP cells. In this last case, the effect of androgens was dependent on RNA 
synthesis and occurred in a dose- and time-dependent manner [91]. The mechanism as to 
how androgens down-regulate JNK activation is unknown. The goal of this study was to 
investigate the possible role of MKPs in androgen-induced inhibition of JNK activation 
and their subsequent involvement in androgen-mediated protection of LNCaP cells from 
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Regulation of MAPK phosphatase expression in the prostate cancer cell 
line LNCaP - Possible role in apoptosis 
Summary 
Androgen ablation during the initial stages of prostate cancer causes regression of the 
tumor due to an increase in apoptosis and reduced cellular proliferation. However, some 
prostate cancer cells survive in the androgen deprived environment and prostate cancer 
invariably progresses to an androgen-independent state for poorly understood reasons. Two 
different agents, 12-O-tetradecanoylphorbol-13-acetate (TPA) and thapsigargin (TG) 
activate c-Jun N-terminal kinase (JNK) and induce apoptosis in the androgen-responsive 
prostate cancer cell line LNCaP. Previous results from our laboratory show that androgen 
treatment of LNCaP cells protects them from TPA- and TG-induced apoptosis due to 
down-regulation of JNK activation. Ultraviolet light (UV)-induced JNK activity was also 
inhibited by androgens in LNCaP cells. Gene expression was required for this inhibition 
and ATP depletion experiments indicated an increase in phosphatase activity. This 
suggested a possible role for the MAPK phosphatases (MKPs) in inactivating JNK during 
inhibition of apoptosis in LNCaP cells; this is consistent with other data from our 
laboratory that showed an up-regulation of MKP-1 in cells treated with apoptosis inducing 
agent TPA and R1881, synthetic androgen. In this study, we have investigated the possible 
regulation of MKPs in UV, TPA, or TG treated cells in the presence or absence of R1881 
and the data show that some MKPs are up-regulated in the presence of R1881 and TPA or 
TG. All tested MKPs were significantly down-regulated at the mRNA level in cells 
exposed to UV irradiation; R1881 did not appreciably affect MKP expression that is 
inhibited by UV. Analysis of TPA- and TG-induced apoptosis in LNCaP cells ectopically 
expressing VHR wild-type or a catalytically inactive mutant indicated that VHR interferes 
with apoptosis. In summary, these data indicate a role for the MKPs in the down-regulation 
of JNK activation in LNCaP cells and may be at least part of the mechanism as to how 
androgens inhibit JNK activation.  
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Introduction 
Apoptosis is a physiological cell suicide program that is critical for the development and 
maintenance of healthy tissues. It is necessary for sculpting embryos, maintaining tissue 
homeostasis, terminating immune responses, and restricting the process of infections. This 
process involves many factors that are all tightly regulated and deregulation may cause 
severe damage leading to many diseases, including cancer, autoimmunity, and 
degenerative disorders [1]. Cells that are undergoing apoptosis typically display several 
morphological changes including cell shrinkage, loss of contact with neighbouring cells, 
chromatin condensation, blebbing of the plasma membrane, and fragmentation into 
apoptotic bodies [2, 3].  
Signaling pathways that have been implicated in the regulation of apoptosis are the 
mitogen-activated protein kinase (MAPK) pathways. The MAPK cascades play an 
important role in transduction of environmental stimuli to the transcriptional machinery in 
the nucleus by virtue of their ability to phosphorylate and regulate the activity of various 
transcription factors [4-6]. The MAPK cascades are composed of three protein kinases 
acting in series activating one another by phosphorylation. A MAPK is activated by a 
MAPK kinase (MAPKK) which in turn is activated by a MAPKK kinase (MAPKKK) [4, 
7]. In mammals, there are three main MAPKs, extracellular-signal regulated kinase (ERK), 
c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and p38 MAPK. The 
ERK pathway is typically stimulated by growth-related signals and is mainly involved in 
growth, differentiation, and development. p38 MAPK and JNK are activated by growth 
factors, pro-inflammatory cytokines, and cellular stress and their activation has been 
implicated in apoptosis, as well as in oncogenic transformation, inflammation, 
development, and differentiation [8, 9]. JNK protein kinases are encoded by three genes, 
JNK1, JNK2, and JNK3 that are alternatively spliced to create ten isoforms [10]. The 
JNK1 and JNK2 genes are expressed ubiquitously whereas the JNK3 gene has a more 
limited pattern of expression and is largely restricted to brain, heart, and testis [11]. The 
cell type, magnitude, and duration of the stimulus determine the biological effect of JNK 
signaling and leads to phosphorylation and activation of several downstream effectors [12-
15]. 
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The MAPK pathways can be inactivated by tyrosine phosphatases (PTPs), 
serine/threonine phosphatases, and dual specificity phosphatases/MAPK phosphatases 
(DUSPs/MKPs). These phosphatase families are implicated as central regulators of 
mitogenic and other signaling pathways mediated by the MAPK pathways [16]. The 
MKPs, in contrast to the two other phosphatase families, specifically dephosphorylate the 
MAPKs at phosphorylated threonine/serine and tyrosine residues located in the activation 
loop of the MAPKs. To date there are fourteen known MKPs that are known to have 
different subcellular localization (nuclear, cytosolic, or both), MAPK affinity, and 
structure. In fact, this indicates great complexity for the negative regulation of MAPK 
signaling [17]. MKP-1/DUSP1 was the first MKP to be discovered in 1991 and was shown 
to have significant sequence homology to the VH-1 gene coding for a phosphatase in 
vaccinia virus [18]. One MKP of interest in this study is VHR/DUSP3 which was shown to 
effectively dephosphorylate both ERK and JNK [19, 20]. VHR (VH1-related) was first 
discovered in 1992 by Ishibashi et al. This protein had sequence homology to the VH1 
gene in vaccinia virus and it was shown to be a phosphatase with dual specificity based 
upon its ability to hydrolyze phosphoserine from casein as well as phosphotyrosine from a 
number of tyrosine-phosphorylated growth factor receptors [21]. The cysteine (Cys124) 
situated in the catalytic domain is essential for catalysis and mutation of Cys124 to a serine 
completely abrogates the enzymatic function of VHR, indicating the importance of this 
amino acid [22, 23]. 
The androgen receptor (AR) belongs to the nuclear receptor superfamily [24]. Like 
other members of this family it is characterized by an N-terminal domain for 
transcriptional regulation, a centrally located DNA-binding domain, and a ligand-binding 
domain at the C-terminal end [25]. AR binds androgens which play an important role in 
regulating growth, differentiation and cell death responses in the normal and cancerous 
prostate [26]. During the initial stages of prostate cancer an increased rate of apoptosis and 
a decreased rate of cell growth is observed after androgen depletion and results in 
regression of the tumor [27]. However, prostate tumors include androgen-independent 
prostate cancer cells which survive in an androgen depleted environment and so the disease 
progresses to an androgen-independent state. Many different adaptive survival factors are 
found in androgen-independent cells such as amplification of the AR gene, hypersensitivity 
of the AR to androgens, AR mutations that allow non-specific ligand binding, deregulated 
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expression of coactivators that may enhance AR-dependent gene transcription, and up-
regulation of survival genes such as anti-apoptotic Bcl-2 [28-30]. To date the molecular 
mechanisms of transition from androgen-dependence to androgen-independence remain 
poorly understood and little is known about the link between androgens and the apoptosis 
signaling pathways in prostate cancer. 
Previously, 12-O-tetradecanoylphorbol-13-acetate (TPA) and thapsigargin (TG) were 
shown to induce apoptosis through a mechanism that requires JNK activation in the 
androgen-responsive prostate cancer cell line LNCaP [31]. JNK activation in response to 
TPA and TG shows a biphasic activation profile with activation of JNK at 30 minutes of 
treatment which is reduced to basal levels by 6 hours, followed by a second sustained JNK 
activation that correlates with an increase in apoptosis. Highly significant levels of 
apoptosis were observed at 12 and 24 hours of TPA treatment, and at 36 and 48 hours of 
TG treatment. The effect of TPA on apoptosis was not observed in androgen-independent 
cell lines (PC-3, DU-145 and HeLa), indicating a different role of TPA on androgen-
responsive and androgen-independent cell lines [31]. Therefore, additional studies to 
unravel the molecular mechanisms of JNK signaling and apoptosis in prostate cancer cells 
are needed. Previous results in our laboratory showed that androgens protect LNCaP cells 
from TPA- and TG-induced apoptosis and that this response is mediated by the down-
regulation of JNK activation. In addition, androgens inhibited UV irradiation-induced JNK 
activation and this response is dose- and time- dependent, dependent on AR, and requires 
de novo gene transcription [32]. The cells treated with androgens had a faster rate of JNK 
dephosphorylation than vehicle treated cells and this suggested that phosphatases may, at 
least in part, mediate inhibition of JNK by androgens [32]. Furthermore, the phosphatase 
MKP-1 was up-regulated in TPA and R1881 treated LNCaP cells compared to cells treated 
with TPA alone. It was therefore of interest to further investigate the expression and 
regulation of the MKPs in LNCaP cells treated with TPA, TG, or UV irradiation in the 
presence or absence of R1881 and to assess if they could play an essential role in reducing 




Materials and Methods 
Materials 
pcDNA3-VHR, pcDNA3-VHR-C124S, and anti-VHR rabbit polyclonal antibody were 
generous gifts from John M Denu. RPMI 1640, penicillin/streptomycin and L-glutamine 
were purchased from BioWhittaker-Cambrex. R1881, 12-O-tetradecanoylphorbol 13-
acetate (TPA), thapsigargin (TG), fetal calf serum (FCS), oligo dT, Triton X-100, HePes, 
NaCl, EDTA, MgCl2, dithiothreiol (DTT), β-glycerophosphate, sodiumortovanadate, 
phenylmethylsulphonyl-fluoride (PMSF), leupeptin, dimethyl sulfoxide (DMSO), Tween 
20, bovine serum albumin (BSA), ampicillin, anti-α-Tubulin mouse monoclonal antibody, 
horseradish peroxidase-conjugated anti-rabbit IgG antibody, horseradish peroxidase-
conjugated anti-mouse IgG antibody, and DAPI were obtained from Sigma-Aldrich. 
TRIzol® Reagent, Superscript II reverse transcriptase, Alexa fluor 594-linked goat anti-
rabbit IgG, and Alexa fluor 488-linked goat anti-rabbit IgG were purchased from 
Invitrogen. Lightcycler® Faststart DNA Master SYBR green, In Situ cell death detection 
kit, and FuGene 6 were from Roche Diagnostics. ECL Western Blotting Analysis System 
was from Amersham Pharmacia Biotech. Bradford solution, Precision Plus Protein dual 
protein standard, and PVDF membrane were obtained from Bio-Rad. JETstar midi-prep kit 
was obtained from Genomed. Paraformaldehyde was purchased from Electron Microscopy 
Sciences. Anti-ph-JNK rabbit polyclonal antibody and anti-total JNK rabbit antibody were 
purchased from Cell Signaling.  
Cell culture 
The human prostate cancer cell line LNCaP was purchased from the American Type 
Culture collection (Rockville, MD). The passage number for LNCaP cells was always 
between 15 and 30. Cells were routinely kept in a humidified 5% CO2 and 95% air 
incubator at 37ºC in RPMI 1640 containing 10% fetal calf serum (FCS), 50 U/ml 
penicillin, 50 µg/ml streptomycin and 2 mM L-glutamine. Medium was changed every 
second day. For experiments cells were plated in RPMI 1640 containing 10% FCS at a 
density of 1.6×105 cells per well in six-well plates or 9×105 cells per 10 cm dish. Cells 
were serum starved for two days in medium containing 2% charcoal treated (CT)-FCS to 
deplete the cells from androgens and to lower the basal level of JNK. The cells were 
starved further for 10 hours in medium provided with 0.5% CT-FCS. For the UV 
experiments the cells were treated with synthetic androgen, R1881 [10-7M], or ethanol 
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vehicle and at the indicated time points the cells were subjected to UV irradiation (2 J/cm2 
for 5 seconds). After further incubation at 37ºC for 30 minutes the cells were collected by 
scraping the wells with phosphate-buffered saline (PBS). For the experiments involving 
12-O-tetradecanoylphorbol 13-acetate (TPA) and thapsigargin (TG) treatment, cells were 
cultured as above. After starvation, cells were either left untreated or treated with R1881 
[10-7M] for 40 hours before adding TPA (5 ng/ml) or TG (100 nM). TPA stock solution 
was 5 µg/ml in ethanol and TG stock solution was 100 µM in DMSO. The cells were then 
collected after 6h, 12h, 24h, 36h and 48h as indicated. Ethanol or DMSO was used as 
vehicle.   
Real-time RT-PCR 
Total RNA was extracted from cell pellets with TRIzol® Reagent according to the 
manufacturer’s instructions. RNA concentrations and purity were measured with a 
Lambda25 spectrophotometer (Perkin Elmer Life Sciences) at 260nm and 280nm. mRNA 
(2-5µg) was reverse transcribed using Superscript II reverse transcriptase and oligo dT. 
PCR amplification was performed on a lightcycler (Roche) using Lightcycler® Faststart 
DNA Master SYBR green as a DNA-specific binding dye and for continuous fluorescence 
monitoring. PCR conditions included an initial denaturation step at 95ºC for 10 minutes 
followed by 45 cycles of 95ºC denaturation for 10 seconds, annealing for 5 seconds (for 
specific annealing temperature for each primer pair see Table 1) and 72ºC extension for 20 
seconds. Analysis was carried out in lightcycler capillaries with 10 µl reaction volumes 
containing 0.25 µl SYBR green, 2-4 mM MgCl2, 0.5 µM of each primer and 2 µl of cDNA 
template. Template dilution, MgCl2 concentrations and temperature conditions were 
optimized for each primer pair. Primers were designed using the Primer 3 program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and each primer pair bound to 
an exon flanking a large intron to avoid amplification of genomic DNA. Melting curve 
analysis was done after each PCR reaction and the level of expression for each mRNA was 
determined using the crossing points given by the Lightcycler computer software. For each 
sample the ratio between the relative amounts of the target gene and housekeeping gene 




Table 1. The sequence of the primers used and the reaction conditions   








cgtctgtggctcaggacatc cattgagctggcagagttgg 1:2 2 mM 66  ْC 
DUSP-
5/ VH3 
acaggccagcttatgaccag gagaccatgctcctcctctg 1:2 2 mM 62  ْC 
DUSP-
6/ 
gctgctgctcaagaagctca aattgggggtgacgttcaag 1:2 2 mM 62  ْC 
DUSP-
7/ MKP-
ctgtccagatcctgccctac ccccatgaagttgaagttgg 1:2 3 mM 63  ْC 
DUSP-
9/ 
cagatcctgcccaacctcta actgccccatgaagttgaag 1:2 2 mM 63  ْC 
DUSP10
/MKP5 
cttgcccttcctgttccttg agcaactgccccatgaagtt  4mM 64  ْC 
DUSP14
/MKP6 





 2 mM 63  ْC 
DUSP22
/ DSP2 
agcggattcaccatctcaaa cagcaccagcctaaactctg 1:10 2 mM 63  ْC 
TBP gaatataatcccaagcggtttg acttcatcacagctcccc 1:10 3 mM 62  ْC 
GAPDH ggcctccaaggagtaagacc aggggtctacatggcaact
g 
1:2 2,9 mM 60  ْC 
 
Western blot analysis 
Whole cell extracts were obtained by resuspending the cell pellets in 100 µl lysis buffer 
containing 0.1% Triton X-100, 20 mM HePes (pH 7.7), 300 mM NaCl, 0.2 mM EDTA, 1.5 
mM MgCl2, 0.5 mM DTT, 20 mM β-Glycerophosphate, 0.1 mM sodiumortovanadate, 0.5 
mM PMSF, and 2 µg/ml leupeptin. After rotating for two hours at 4ºC, the suspension was 
centrifuged at 13,000 rpm for 10 minutes and the supernatant was collected. All protein 
concentrations were determined utilising the Bio-Rad protein assay. Equal amounts of 
protein (100 or 200 µg) were separated on 12% SDS-page gels. A Precision Plus Protein 
dual protein standard was used as molecular weight marker. Proteins were transferred to a 
PVDF membrane activated in methanol. The blotted membrane was blocked in 5% nonfat 
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dry milk in Tris-buffered saline (TBS) containing 0.1% Tween for one hour followed by 
incubation with primary antibody in TBS-Tween containing 5% bovine serum albumin 
(BSA) for 14-16 hours at 4ºC. Antibodies used were anti-VHR rabbit polyclonal antibody 
(1:5000 dilution), anti-ph-JNK rabbit polyclonal antibody (1:500 dilution), anti-total JNK 
rabbit antibody (1:500 dilution) and anti-α-Tubulin mouse monoclonal antibody (1:5000 
dilution). The membranes were incubated with secondary antibodies in 5% nonfat dry milk 
dissolved in TBS-Tween for 1 hour at room temperature. Secondary antibodies used were 
horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:10000 dilution) or 
horseradish peroxidase-conjugated anti-mouse IgG antibody (1:5000 dilution). ECL 
Western Blotting Analysis System was utilized for detection of the immunoreactive bands 
according to the manufacturer’s instructions.  
Bacterial expression and purification of plasmids 
Electroporation was used to transform pcDNA3-VHR and pcDNA3-VHR-C124S into 
electro competent bacteria (DH10B). The electroporation procedure was carried out at 1.3 
Volt (200 Ω) and bacteria were allowed to grow for one hour in LB before they were 
plated out on agar plates containing ampicillin (100 ug/ml). Colonies containing positive 
clones were grown overnight and the JETstar midi-prep kit was utilized to purify the 
plasmids. The plasmids were then digested with the appropriate restriction enzymes to 
verify their identity.  
TUNEL assay 
        LNCaP cells were grown on cover slips in six-well plates containing 1.4×105 cells per 
well. They were starved as described above and transfected with pEGFP, pcDNA3-VHR or 
pcDNA3-VHR-C124S in medium containing 2% CT-FCS. FuGene 6 was used as 
transfection reagent according to the manufacturer’s protocol. The FuGene:DNA ratio was 
optimized and kept at 3:1. The cells were treated with TPA (5ng/ml) or TG (100nM) for 
the indicated times and fixed for 20 min in 4% paraformaldehyde followed by 10 min in 
cold methanol at -20ºC. After 2 washes with PBS, cells were permeabilized with 0.1% 
Triton X-100 in PBS for 5 min. Cover slips were blocked by incubation with 5% BSA in 
PBS-Triton X-100 0.1% for one hour at room temperature and after 3 washes with PBS the 
cells were incubated with primary antibody, anti-VHR rabbit antibody (dilution 1:1000), in 
3% BSA in PBS or in 3% BSA in PBS without antibody as a negative control, overnight at 
4ºC. Secondary antibodies Alexa fluor 594 or 488-linked goat anti-rabbit IgG were left on 
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the cells for one hour at room temperature. To detect apoptosis, an In Situ cell death 
detection kit (TUNEL technology) was used according to the manufacturer’s instructions. 
Either In Situ cell death detection kit-Fluorescein or In Situ cell death detection kit-TMR 
Red was utilized to detect apoptosis in the cells. DNA strand breaks that typically occur 
with programmed cell death are by the aid of Terminal deoxynucleotidyl transferase (TdT) 
being labelled with fluorescein labelled nucleotides to the free 3’-OH DNA ends (TUNEL-
reaction). To visualize cell nuclei, cells were counterstained with DAPI (1:1000 dilution). 
Fluorescence was observed using an Axioplan2 imaging microscope (Zeiss) and pictures 
were taken with an AxioCam HRc camera (Zeiss). At least three areas and a minimum of 
300 cells per area were counted and the number of TUNEL-positive cells was expressed 
per 100 of the total number of cells.  
Statistics 
Statistical analysis was performed using the Student’s t-test. Values of p < 0.05 were 












Expression and regulation of MKPs in TPA or TG treated LNCaP cells 
Previously it was shown that androgens reduce TPA- or TG-induced apoptosis in 
LNCaP cells through down-regulation of JNK activation. Furthermore, androgens inhibited 
UV irradiation-induced JNK activation and this response occurred in a dose- and time-
dependent manner, requires de novo gene transcription, and indicated an increase in 
phosphatase activity [32]. In addition, earlier work indicated that MKP-1 is up-regulated in 
TPA and R1881 treated LNCaP cells in contrast to cells treated with TPA alone [32-34]. 
For these reasons, the expression and regulation of members of the MKP family that 
specifically dephosphorylate MAPKs was investigated. To investigate this, the mRNA 
expression level for several MKPs was determined by real-time RT-PCR. LNCaP cells 
were treated with synthetic androgen R1881 for 40 hours to optimally block JNK 
activation before TPA or TG was added. Cells were harvested at the indicated times, total 
RNA was extracted from the cells, and cDNA was made and used for real-time PCR. 
Differential mRNA expression patterns were obtained as summarized in Table 2. 
 
Table 2. Regulation of different MKPs at mRNA level in response to TPA+R1881 or TG+R1881. 
LNCaP cells were treated with R1881 [10-7M] and TPA or TG as described in Materials and Methods. The 
mRNA expression levels of the different MKPs (relative to TBP expression) were measured by real-time RT-
PCR. The results presented illustrate the average mRNA expression level of three independent experiments in 
duplicate and are presented as +: up-regulation, -: down-regulation, NC: no significant regulation in 
TPA/TG and R1881 treated cells compared to TPA/TG treated cells. 
Name TPA+R1881 TG+R1881 
DUSP-3/ VHR + + 
DUSP-5/ VH3 + + 
DUSP-6/  MKP3 - NC 
DUSP-7/ MKP-X - NC 
DUSP-9 /MKP4 - NC 
DUSP-14/ MKP6 + NC 
DUSP-22/ DSP2 NC - 
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As mentioned above, TPA and TG activate JNK in a biphasic manner, with an increase 
of JNK activity at half an hour of treatment, followed by a reduction to basal levels and a 
second activation at 6 hours of treatment. The mRNA expression of the MKPs was 
investigated in short and long time courses of TPA and TG treatment including half an 
hour and 6 hour treatments. The MKPs with the most interesting up-regulation in TPA and 
R1881 treated cells (although the level of up-regulation was different) are MKP-6, VHR, 
and VH3 (Fig 1). In addition, as noted above, MKP-1 was previously shown to be up-











































































































Figure 1. Up-regulation of MKP-6, VHR, and VH3 in LNCaP cells treated with R1881 and TPA. 
LNCaP cells were grown and treated with TPA and R1881 for the indicated times as pointed out in Materials 
and Methods. CTRL cells were incubated with R1881 or vehicle for 8 and 48 hours in the short and long time 
courses, respectively. The expression level of MKP-6 (A), VHR (B), and VH3 (C) mRNA (relative to TBP 
mRNA expression) were measured by real-time RT-PCR. Values represent the mean ± SE of three 
independent experiments performed in duplicate. * p<0.05 indicate significant difference between TPA and 
R1881 treated cells versus TPA treated cells. 
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As observed in Figure 1A, the expression level of MKP-6 mRNA has a significant 1.5 
fold increase at half an hour of TPA and R1881 treatment in contrast to TPA treated 
LNCaP cells. In addition, a significant three fold increase at 6 hours of TPA and R1881 
treatment compared to TPA treated cells was observed in both time courses (Fig. 1A). 
After 6 hours the expression level is lower but still a significant increase is observed in 12 
and 24 hour treated cells with TPA and R1881. In addition, it is significantly up-regulated 
in R1881 treated control cells compared to vehicle treated control cells in the long time 
course of treatment (Fig. 1A). VHR is another MKP that was significantly up-regulated. It 
is up-regulated approximately two fold in all the time points of TPA and R1881 treatment 
compared to TPA treated cells in both the short and long time courses of treatment (Fig. 
1B). As for MKP-6, VHR is up-regulated in R1881 treated control cells versus vehicle 
treated control cells in the long time courses of treatment (Fig. 1B). The final MKP that 
showed a significant up-regulation is VH3. The expression of this phosphatase was only 
assessed in a long time course of TPA treatment and is significantly up-regulated 
approximately three fold from 6 to 48 hours with TPA and R1881 treatment (Fig. 1C). In 
addition, it is up-regulated two fold in R1881 treated control cells compared to vehicle 
treated control cells.  
Figure 2 shows the expression and regulation of VHR and VH3 mRNA in TG treated 
LNCaP cells. VHR is significantly up-regulated at 6 to 12 hours of TG and R1881 
treatment compared to TG treated cells in short and long time courses of treatment and is 
significantly down-regulated at 48 hours of treatment. Furthermore, VHR is significantly 
up-regulated in R1881 treated control cells compared to vehicle treated control cells in the 
long time courses of treatment (Fig. 2A). The expression of VH3 was only assessed in long 
time courses of TG treatment. It is significantly up-regulated approximately two fold at 6 
hours and three fold at 48 hours of TG and R1881 treatment. In addition, it is up-regulated 
three fold in the R1881 treated control cells in contrast to vehicle treated control cells (Fig. 
2B). The results from these experiments indicate that certain MKPs are up-regulated in 
R1881 and TPA or TG treated LNCaP cells and they may have essential roles in the down-






























































Figure 2. Up-regulation of VHR and VH3 in LNCaP cells treated with TG and R1881. LNCaP cells 
were grown and treated with TG and R1881 for the indicated times as pointed out in Materials and Methods. 
CTRL cells were incubated with R1881 or vehicle for 8 and 48 hours in the short and long time courses, 
respectively.  The expression level of VHR (A) and VH3 (B) mRNA (relative to TBP mRNA expression) were 
measured by real-time RT-PCR. Values represent the mean ± SE of three independent experiments performed 
in duplicate. * p<0.05 indicate significant difference between TG and R1881 treated cells versus TG treated 
cells. 
 
VHR is up-regulated at the protein level in TPA and TG treated LNCaP cells 
VHR was chosen for further studies because of its significant up-regulation in both TPA 
and TG treated cells in the presence of R1881. In addition, this phosphatase has been 
shown to effectively dephosphorylate JNK [19]. To assess whether the regulation of VHR 
at the protein level is the same as the previously observed regulation at the mRNA level, 
whole cell extracts from TPA and TG treated cells with or without R1881 were examined 
by Western blot analysis using a VHR antibody. The result is shown in Figure 3. The 
increase of protein expression in cells treated with TG and R1881 compared to TG treated 
cells (Fig. 3A and B) gives a good indication of the expression of this phosphatase at 
protein level, although this result is not supporting the data for some of the time points of 
treatment obtained above for VHR mRNA (Fig. 2A). An up-regulation at protein level was 
also observed in LNCaP cells treated with TPA and R1881 in contrast to TPA treated cells 
only (Fig. 3C and D) and corresponds with the result of VHR expression at mRNA level 
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(Fig. 1B) where it is significantly up-regulated. However, VHR is highly up-regulated in 
R1881 treated control cells compared to vehicle treated control cells, indicating an effect of 
R1881 alone on VHR. Thus, the results indicate an increase in VHR protein expression in 
TPA- or TG-induced LNCaP cells treated with R1881 although the experiments need to be 
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Figure 3. VHR protein expression is up-regulated after treatment with R1881 and TPA or TG. LNCaP 
cells were grown, starved, and incubated with R1881 [10-7M] for 40 hours. Thereafter TPA (5ng/ml) or TG 
(100 nM) was added and cells were harvested at the indicated times. CTRL cells were incubated with R1881 
or vehicle for 48 hours. Whole cell extracts were obtained and 200 µg of protein was used for western blot 
analysis. Immunoreactive VHR protein levels after TG treatment (A) or TPA treatment (C) were quantified, 
normalized to the intensity of the immunoreactive α-tubulin bands and expressed relative to the vehicle-
treated controls. The VHR/α-tubulin ratios are plotted in a bar-graph showing the result for TG in B) and for 




Expression and regulation of the different MKPs in LNCaP cells irradiated with UV-
light 
UV irradiation is known to be another activator of JNK [35, 36]. Previously it was 
shown that androgens down-regulate UV-induced JNK activation and that this effect on 
JNK was dependent on the time of androgen exposure. Androgen treatment shorter than 12 
hours gave no significant decrease in JNK activation, whereas treatments up to 48 hours 
nearly blocked all activation [32]. To assess the role of the MKPs in reducing JNK 
phosphorylation, LNCaP cells were treated with R1881 for the indicated times and 
exposed to UV irradiation. Real-time RT-PCR was utilized to investigate the level of 
mRNA expression of the MKPs. The data obtained for MKP-6 and VHR are shown in 
Figure 4A and B, respectively. The mRNA expression of the MKPs was surprisingly low 
compared to the controls and no significant up-regulation was observed in cells treated 












































Figure 4. Reduced expression of MKP-6 and VHR in UV-irradiated LNCaP cells. LNCaP cells were 
grown and treated as described in Materials and Methods. cDNA was made from isolated mRNA and  the 
expression levels of  MKP-6 and VHR (relative to GAPDH mRNA expression) were measured by real-time 
PCR. Real-time RT-PCR results for MKP-6 (A) and VHR (B) are shown. The values represent the average of 





In addition, the mRNA expression of MKP-4, MKP-5, MKP-X, DUSP-22, and MKP-7 
was investigated and approximately the same expression pattern was observed as shown 
for MKP-6 and VHR (data not shown). No real-time RT-PCR results were obtained for 
MKP-3 and VH3 possibly because of too low expression levels. In conclusion, these 
results indicate that the expression levels of the MKPs are low in cells irradiated with UV-
light although some MKPs are slightly up-regulated in the presence of R1881. Further 
studies are needed to investigate the low expression levels of the MKPs in UV irradiated 
cells.  
VHR protein expression is up-regulated after treatment with R1881 and UV irradiation 
To investigate the regulation of VHR at the protein level in UV irradiated cells, whole 
cell extracts were obtained from LNCaP cells treated or untreated with R1881 and UV 
irradiated to activate JNK at the indicated times. Western blot analysis was done to assess 
protein expression of phosphorylated JNK, total JNK, and VHR (Fig. 5). The results verify 
the down-regulation of activated JNK in R1881 treated and UV irradiated cells as 
previously shown [32]. VHR is highly expressed in non-irradiated, R1881 treated control 
cells compared to vehicle treated cells. This does not correspond with the result obtained 
for VHR mRNA expression (Fig. 4B). In addition, the results show that VHR is slightly 
down-regulated at 12 hours of treatment but is up-regulated approximately 2- and 3-fold at 
24 and 48 hours, respectively. In conclusion, these results show that when JNK activation 
is reduced by R1881 treatment in UV irradiated cells to activate JNK, VHR protein 
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Figure 5. VHR protein expression is up-regulated after treatment with R1881 and UV irradiation. 
LNCaP cells grown and treated as previously described. UV irradiation was performed at the indicated 
times. CTRL cells were incubated with R1881 or vehicle for 48 hours. A) Whole cell extracts were prepared 
and 100 µg of protein was used for western blot analysis. Immunoreactive phospho-JNK protein levels after 
R1881 treatment and UV irradiation were quantified and normalized to the intensity of the immunoreactive 
total-JNK bands. VHR protein levels were quantified and normalized to the intensity of the immunoreactive 
α-tubulin band. Ratios for phJNK/totJNK (B) and VHR/ α-tubulin (C) are presented in bar graphs. The 
results are expressed relative to the vehicle-treated controls and represent one experiment. 
 
Ectopic expression of VHR protects LNCaP cells from TPA- and TG-induced apoptosis 
As described above, VHR was found to be up-regulated both at the mRNA and protein 
level in LNCaP cells treated with R1881 and TPA or TG. Up-regulation of this 
phosphatase in the presence of R1881 could be involved in the down-regulation of JNK 
activation in LNCaP cells undergoing apoptosis. In order to elucidate the role of up-
regulated VHR, TUNEL assay was performed on cells transiently transfected with pEGFP, 
VHR wild-type, or mutant VHR-C124S. The cells were grown in the presence or absence 
of R1881 and apoptosis was induced with TPA or TG. At the indicated times the cells were 
fixed, incubated with VHR antibody, and TUNEL assay was performed. Apoptosis was 
investigated at two different times of treatment, 12 and 24 hours for TPA, and 36 and 48 
hours for TG, respectively, according to substantial levels of cell death shown in earlier 
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experiments carried out in the lab [31]. Figure 6 shows the results for one of these 
treatments (TG 48h). Non-treated cells, either transfected with pEGFP, VHR-wt, or VHR-
C124S, are undergoing less apoptosis than TG treated cells for 48 hours as the TUNEL 
staining indicates in the right panel. In addition, cells ectopically expressing VHR-wt are 
undergoing less apoptosis than cells expressing VHR-C124S as shown in the centre panel.  
Quantification of the incidence of apoptosis in these treatments is shown in Figure 7. 
Compared to control cells, apoptosis was significantly reduced in cells ectopically 
expressing VHR wild-type. However, cells transfected with the dominant-negative mutant 
of VHR, pcDNA3-VHR-C124S, were undergoing apoptosis but not to the same extend as 
for non-transfected cells. In order to investigate whether the transfection procedure itself 
had influence on the process of apoptosis, cells were transfected with pEGFP. No 
significant difference in apoptosis in non-transfected and transfected cells was detected, 
thus confirming that the transfection procedure had no or little influence on cell death. The 
results are similar for cells treated either with TPA (Fig. 7A) or TG (Fig. 7B), showing a 
reduction in apoptosis in VHR transfected cells in contrast to VHR-C124S transfected 
cells. From these results it can be suggested that ectopically expressed VHR is able to 
reduce apoptosis in TPA or TG treated LNCaP cells to a greater extent than its catalytically 
















Figure 6. Ectopic expression of VHR protects LNCaP cells from TG-induced apoptosis. LNCaP cells 
were cultured on cover slips and were transiently transfected with pEGFP, VHR-wt, or VHR-C124S. The 
cells were further grown in the presence or absence of R1881 and TG as described experimentally. After 
fixation, VHR transfected cells were incubated with VHR-antibody, TUNEL assay was performed, and cells 
were counterstained with DAPI. TUNEL positive cells appear as green or red fluorescent dots. Arrows 
indicate apoptotic cells. DAPI staining,VHR immunofluorescence, and TUNEL staining is shown for pEGFP-












































































Figure 7. Ectopic expression of VHR reduces apoptosis in LNCaP cells treated with TPA or TG. Cells 
were grown as above. For microscopy, at least three areas and a minimum of 300 cells per area were 
counted. The data show the percentage of nonviable cells after A) 12 and 24 hours of TPA treatment or B) 36 
and 48 hours of TG treatment. For 12 hour treatment with TPA and 48 hour treatment with TG an average of 
one experiment in duplicate ± SE is shown. For 24 hour treatment with TPA and 36 hour treatment with TG 
an average of 2 experiments in duplicate is shown. * p<0.05 indicates significant difference from non-






Intracellular signal transduction pathways are key regulators of a number of cellular 
functions. The MAPK signaling pathways have been implicated in such diverse cellular 
processes as differentiation and apoptosis. To regulate the cellular responses, the timing of 
activation and inactivation of these kinases must be strictly regulated. This can be achieved 
either by regulation of activation, i.e. phosphorylation, or regulation of inactivation, i.e. 
dephosphorylation.  
The data presented here show that members of the MKP family may have an important 
role in the inhibition of the JNK pathway in TPA or TG treated LNCaP cells. We have 
found that three different phosphatases, MKP-6, VHR, and VH3, are significantly up-
regulated at the mRNA level in cells treated with R1881 and TPA compared to cells 
treated with TPA alone. In addition, VHR and VH3 were shown to be up-regulated in 
R1881 and TG treated cells compared to cells treated with TG alone. Consistent with up-
regulated VHR mRNA, VHR was also up-regulated at the protein level. However, R1881 
alone could influence MKP expression since VHR mRNA and protein was up-regulated in 
R1881 treated control cells. Cells, including control cells, in TPA and TG experiments are 
pre-treated with R1881 for 40 hours whereas cells in the UV experiments are not. Control 
cells treated with R1881 for 40+48 hours showed an up-regulation of MKP-6, VHR, and 
VH3 compared to vehicle treated control cells. In contrast, control cells treated with R1881 
for 40+8 hours did not give an increase in MKP-6 and VHR mRNA. The R1881 treated 
control cells (6 and 48 hours) in the UV experiments show no up-regulation of MKP-6 and 
VHR compared to vehicle treated control cells. This suggests that R1881 can influence 
mRNA expression of these MKPs in longer treatments (~88 hours) and indicates that a role 
of R1881 alone on the expression of the MKPs needs to be investigated.  
MKP-6, VHR, and VH3 have different affinities for the MAPKs. MKP-6 was shown to 
effectively dephosphorylate ERK and JNK, and to a lesser extent p38 MAPK [37]. VHR 
has been shown to dephosphorylate all three MAPKs but it has the greatest specificity for 
ERK [17, 19, 20]. In contrast to VHR, little is known about the specificity of VH3 towards 
the MAPKs but recently one study showed that it effectively binds ERK, and to a lesser 
degree JNK and p38 MAPK [38].  
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Several studies show that MKP-1 mRNA is over-expressed in high-grade PIN, 
compared to normal prostate and that the proportion of apoptosis is significantly lower in 
PIN lesions expressing MKP-1. Furthermore, JNK1 enzymatic activity was shown to be 
inversely related to MKP-1 levels [33, 34, 39]. The fact that many MKPs are regulated in 
R1881 and TPA or TG treated LNCaP cells, presented here, indicate that these MKPs may 
inhibit JNK activation and thereby block apoptosis. Additional studies are required to 
assess this possibility.  
The TUNEL assay in this study suggests that ectopically expressed VHR reduces TPA- 
and TG-induced apoptosis compared to non-transfected cells, possibly through inactivating 
JNK. In contrast, mutant VHR-C124S transfected cells were undergoing more apoptosis 
compared to VHR transfected cells but here as well there was less apoptosis than in non-
transfected cells. Although cells ectopically expressing the catalytically inactive mutant of 
VHR show a decrease in apoptosis compared to non-transfected cells, VHR wild-type 
transfected cells still have a greater reduction in apoptosis than the mutant VHR 
transfected cells. VHR has previously been demonstrated to down-regulate the JNK 
signaling pathway at the level of JNK dephosphorylation but nothing is known about the 
physiological effects of inactivation of JNK by VHR [19]. Recently MKP-1 was 
demonstrated to promote cell survival by attenuating stress-responsive MAPK-mediated 
apoptosis and suggested participation of other MKPs in this process [40]. Although the 
first MKP was discovered in 1991, not much is known about the mechanism and structural 
basis for recognition of phosphorylated MAPKs by MKPs but it is clearly an important 
level of MAPK signaling pathway regulation. Further experiments are needed to verify if 
the reduction of apoptosis in VHR transfected LNCaP cells is due to a decrease of 
activated JNK; nevertheless, these data indicate that ectopic expression of VHR reduces 
apoptosis.  
One of the findings of this study was that in response to UV irradiation all MKPs tested 
were down-regulated at the mRNA level. It is known that UV irradiation works by 
activating upstream kinase pathways which finally phosphorylate the MAPKs [36]. The 
down-regulation of MKPs by UV indicates that inhibition of phosphatases may be equally 
important in achieving MAPK activation. It is conceivable that MKPs are down-regulated 
in a coordinate manner, e.g. by the deployment of common transcriptional repressors or 
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inhibition of common transcriptional activators. Further work is needed to elucidate these 
possibilities.  
Since the expression of the MKPs is lower in UV irradiated cells than in TPA and TG 
treated cells, this might suggest that the MKPs possibly do not have a role in reducing UV-
induced JNK activation in R1881 treated cells. Recently it was shown that MKP-1 is 
down-regulated in UV irradiated (1 J/m2) transcription-coupled repair deficient fibroblasts 
and this correlated with an increase in JNK activity [41]. This suggests that UV irradiation 
can repress MKP-1 and possibly several other MKPs but further research will be needed to 
assess the role of the MKPs in UV-irradiated LNCaP cells.  
Since the effect of androgen treatment on UV-induced JNK activity was shown to be 
dependent of new gene expression, it will be important to investigate the promoters of the 
different MKPs to assess if they have androgen response elements (AREs) to allow binding 
of ligand-bound AR. MKP-1 does not have an ARE in its promoter and therefore increased 
transcription of this gene is unlikely to be due to binding of ligand-bound AR [42]. In our 
laboratory MKP-1 was previously shown to be up-regulated in cells treated with TPA or 
TG in the presence of R1881 and thus should be caused by other mechanisms. Another 
member of the nuclear receptor superfamily, glucocorticoid receptor, has been indicated to 
inhibit MAPK cascades to regulate inflammatory processes and MKP-1 was shown to have 
an important role in the down-regulation of glucocorticoid activated MAPKs in mast cells 
[43]. MKP-1 has a glucocorticoid response element in its promoter and its expression is 
induced by binding of ligand-bound glucocorticoid receptor to this element [43].  
Knock down of MKP-6, VHR, and VH3 with siRNA should make it possible to observe 
if the effect of androgens on JNK is blocked. It is, however, possible that other MKPs get a 
different regulation in order to bypass the inhibited function of the MKP that is knocked 
down. Since the MKPs have overlapping substrate specificity displayed by members of the 
various subgroups, it seems likely that there will be a certain degree of redundancy [18].  
There are many other phosphatases than included in this study which may be involved 
in modulating JNK activity. For example, in the DUSP family, there is a poorly 
characterized atypical group of DUSPs that lack specific MAPK targeting motifs. The so-
called DUSP13, DUSP19-21, and the recently discovered DUSP15/VHY belong to this 
group. The physiological functions of most of these phosphatases are unknown and most of 
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them have not yet been characterized experimentally [44]. Studies on DUSP19 (also called 
SKRP1) in Cos-7 cells co-expressing JNK2 and SKRP1 have shown that it interacts with 
its physiological substrate JNK2 through binding MKK7, a MAPKK upstream of JNK, and 
inhibits activation of JNK2 induced with TG but not UV irradiation [45].  
Also the action of the threonine/serine phosphatases might explain the down-regulation 
of JNK activation in LNCaP cells treated with R1881 and TPA or TG. They consist of four 
major groups (PP1, PP2A, PP2B and PP2C) in eukaryotes and several distinct isoforms 
exist for these phosphatases [46]. PP2Cα (a PP2C gene product) and PP2A expression was 
shown to strongly inhibit the activation of JNK. PP2Cα  was able to inhibit activation of 
the JNK pathway at the MAPKK level and PP2A was shown to directly inhibit JNK 
activity at the MAPK level [47, 48]. It will therefore be of great interest to investigate the 
regulation of at least these two serine/threonine phosphatases in LNCaP cells with TPA 
and TG induced JNK activation. To date, the third group of phosphatases, the PTPs, have 
not been shown to inactivate JNK.  
Many different signaling pathways are involved in death responses, indicating that no 
simple explanation can be found for the down-regulation of JNK activation, and the 
crosstalk between androgen signaling and the MAPK pathway. Recently, activation of 
androgen receptor by androgen was shown to induce AP-1 activity and to change AP-1 
factor DNA-binding, and may contribute to androgen-induced changes in prostate cancer 
cell growth [49]. Furthermore, JNK activation of c-Jun was shown to result in the 
inhibition of MKP expression and is a way for c-Jun to control the efficiency of MAPK 
signaling [50]. To conclude, our study shows that several MKPs might have a role in 
reducing TPA- and TG-induced JNK activation in androgen treated LNCaP cells. 
Furthermore, ectopically expressed VHR was shown to abolish TPA- and TG-induced 
apoptosis, most likely due to its ability to dephosphorylate and inactivate JNK. The 
findings in this study support the hypothesis that MKP inactivation may be a valid strategy 
to sensitize prostate cancer cell death in combination with conventional cancer 
chemotherapeutic strategies. However, further investigations are required to elucidate the 
specific functions of the MKPs in androgen-mediated down-regulation of JNK activation 
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